Treatment with canakinumab resulted in rapid, sustained improvements in active systemic juvenile idiopathic arthritis, regardless of whether the patient had a fever at initiation, according to ...

Seven-year-old Jack Troyano was diagnosed with systemic juvenile idiopathic arthritis, a rare disease. Jack receives regular treatments including a shot every three weeks and a weekly three-hour ...

We interviewed experts in the field of pediatric rheumatology to understand gaps in juvenile idiopathic arthritis management.

More information: Bruno Fautrel et al, EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's ...

Systemic juvenile idiopathic arthritis (SJIA) isn’t common: It affects about 10 to 15 percent of all people with JIA. It happens when the body’s immune system goes into overdrive and attacks ...

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that biologics were the most common initial treatment prescribed to treat systemic ...

Acute digital clubbing was one clinical characteristic of a rare and potentially fatal lung disease recently observed in a cohort of patients with systemic juvenile idiopathic arthritis, according ...

8 Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: Efficacy Data From the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial. Abstract presented at ACR 2010.

Items Tagged with 'systemic juvenile idiopathic arthritis' ARTICLES. China approves world’s first tocilizumab biosimilar by Bio-Thera. Jan. 18, 2023. By Doris Yu. Bio-Thera Solutions Ltd. has obtained ...

SJIA is not your grandmother’s arthritis. Known as Still's disease in adults, about 300,000 U.S. kids under the age of 16 have JIA. Ten to 20 percent of them have the systemic form, which means the ...

Phase III study showed 85% of treated children with active disease achieved sJIA ACR30. The EC has approved Roche’s RoActemra (tocilizumab) for the treatment of active systemic juvenile ...

Eosinophilia is common among patients with systemic juvenile idiopathic arthritis (JIA) who have been treated with IL-1/IL-6 inhibitors, and severe disease may be associated with both eosinophilia ...